Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_05-md-01699/USCOURTS-cand-3_05-md-01699-911/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1332 Diversity-Product Liability

---

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-1- 

PRETRIAL ORDER NO. 26: SALES REPRESENTATIVE 

DISCOVERY FOR INITIAL MDL TRIALS – M:05-CV-01699-CRB 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO DIVISION 

IN RE: BEXTRA AND CELEBREX 

MARKETING SALES PRACTICES AND 

PRODUCT LIABILITY LITIGATION 

CASE NO. M:05-CV-01699-CRB 

MDL No. 1699 

This Order Relates to: 

 ALL CASES. 

PRETRIAL ORDER NO. 26: SALES 

REPRESENTATIVE DISCOVERY FOR 

INITIAL MDL TRIALS 

I. SCOPE OF ORDER

1. Scope of Order. This Order shall apply to the plaintiffs selected for trial 

pursuant to Pretrial Order No. 25 (“the trial plaintiffs”). Pfizer shall provide the following 

discovery in connection with the sales representatives who detailed the trial plaintiffs’ prescribing 

physician(s) regarding COX-2 inhibitors (“the trial case sales representatives”). 

2. Bextra Trial Plaintiffs. If a trial plaintiff alleges injury only from taking 

Bextra, then Pfizer shall not be required to produce documents for or make available for 

deposition any representative who stopped detailing the prescribing physician(s) before April 

2002 or who did not start detailing the prescribing physician(s) until after April 2005. The term 

“trial case sales representative” shall not include any such representatives. 

///// 

///// 

Case 3:05-md-01699-CRB Document 2035 Filed 11/13/07 Page 1 of 5
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-2- 

PRETRIAL ORDER NO. 26: SALES REPRESENTATIVE 

DISCOVERY FOR INITIAL MDL TRIALS – M:05-CV-01699-CRB 

II. DOCUMENT PRODUCTION

3. Production of Trial Case Sales Representatives’ Custodial Files. Pfizer 

shall produce documents from the custodial files of the trial case sales representatives that are 

related to COX-2 inhibitors, including but not limited to emails; training materials (including 

videotapes, which Pfizer shall make available for inspection or for which plaintiffs may pay 

duplication costs); documents provided to prescribing physicians; correspondence with 

prescribing physicians, managers, or other sales representatives; reports of weekly activity; Field 

Trip Coaching Guide reports; and Goal Attainment Reports (GAR). The parties shall meet and 

confer with respect to whether Pfizer shall provide electronic documents in the trial case sales 

representatives’ custodial files dated after July 31, 2005. 

4. Production of Trial Case Sales Representatives’ Personnel Files. Pfizer 

shall produce personnel files for the trial case sales representatives, including but not limited to 

Year End and Mid Year Performance reviews, in their entirety, with the exception of information 

regarding other products or personal information about the representatives, which Pfizer may 

redact pursuant to Pretrial Order No. 3. 

5. Production of Reports from Pfizer Databases Regarding Trial Case Sales 

Representatives. Pfizer shall produce reports from its databases with the following information 

regarding particular trial case sales representatives to the extent such information is available: 

a. BETSY. Information regarding trial case sales representatives’ 

budget available for speaker programs and how the trial case sales representatives spent their 

budgets. 

b. PEDAGOGUE. Tests the trial case sales representatives took in 

training to detail COX-2 inhibitors and the results of those tests. 

c. Goal Attainment Reports. Goal Attainment Reports by area for 

each area in which a trial case sales representative detailed. 

6. Production of Prescribing Data. Pfizer shall work with its third party 

vendor to facilitate production from that vendor of profiles regarding the trial plaintiffs’ 

///// 

Case 3:05-md-01699-CRB Document 2035 Filed 11/13/07 Page 2 of 5
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-3- 

PRETRIAL ORDER NO. 26: SALES REPRESENTATIVE 

DISCOVERY FOR INITIAL MDL TRIALS – M:05-CV-01699-CRB 

prescribing physician(s), including those physicians’ prescribing history and potential with 

respect to Bextra, Celebrex and Vioxx, as follows: 

a. Deadline for Plaintiffs’ Requests. The Plaintiffs’ Steering 

Committee (“PSC”) shall identify all the prescribing physician(s) for the trial plaintiffs for whom 

they request prescribing data by Friday, November 9 at 4:00 p.m. Eastern time. 

b. Notification of Additional Requests by Pfizer. Pfizer will notify the 

PSC if there are any additional prescribing physician(s) for the trial plaintiffs for whom Pfizer 

will request prescribing data by November 9 at 5:00 p.m. Eastern time. 

c. Transmission of Prescribing Data. Pfizer will request the 

prescribing data from the vendor on November 9 and will transmit the prescribing data to the PSC 

upon receipt. 

d. Cost for Prescribing Data. Pfizer will bear the cost of the initial 

requests on November 9. If the PSC identifies any additional trial plaintiffs’ prescribing 

physician(s) after November 9 for whom they wish to obtain prescribing data, the PSC may do so 

but will bear the full cost of any such request. 

7. Production of District and Regional Managers’ Files. 

a. Regional Managers. Pfizer shall not be required to produce any 

documents relating to regional managers. 

b. District Managers Noticed for Deposition. In connection with 

district managers’ depositions noticed pursuant to paragraph 10 of this Order, Pfizer shall produce 

those managers’ files relating to Bextra and/or Celebrex as follows: (1) any emails sent to or 

received from the trial case sales representatives; (2) Field Trip Coaching Guides relating to the 

trial case sales representatives; (3) any materials related to Plans of Action (“POAs”); and (4) the 

managers’ year-end performance reviews. Pfizer shall not be required to produce any documents 

relating to district managers who are not noticed for deposition. 

8. Compensation of Trial Case Sales Representatives Noticed for Deposition. 

Pfizer shall produce document(s) containing information regarding the salary and bonuses paid to 

the trial plaintiff sales representatives noticed for deposition. Pfizer shall not be required to 

Case 3:05-md-01699-CRB Document 2035 Filed 11/13/07 Page 3 of 5
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-4- 

PRETRIAL ORDER NO. 26: SALES REPRESENTATIVE 

DISCOVERY FOR INITIAL MDL TRIALS – M:05-CV-01699-CRB 

produce documents regarding compensation for the trial plaintiff sales representatives who are 

not noticed for deposition or for district or regional managers. 

9. Deadline for Document Production. 

a. Custodial Files, Personnel Files, Database Reports, and Prescribing 

Data for Trial Case Sales Representatives. Pfizer shall produce the custodial files, personnel files, 

applicable database reports, and prescribing data required by paragraphs 3 through 6 of this Order 

on a rolling basis and in no event later than December 21, 2007. Pfizer shall provide custodial 

files for at least five (5) trial case sales representatives by Friday, November 30; at least five (5) 

more such custodial files by Friday, December 7; and at least five (5) more such custodial files by 

Friday, December 14, with any remaining custodial files, personnel files, database reports, and 

prescribing data by Friday, December 21. 

b. Files of District Managers Noticed for Deposition. Pfizer shall 

produce the file of any district manager noticed for deposition as required by paragraph 7(b) of 

this Order at least ten (10) days before the district manager’s deposition. 

c. Compensation of Trial Case Sales Representatives Noticed for 

Deposition. Pfizer shall produce the information required by paragraph 8 of this Order at least 

five days (5) before the trial case sales representative’s deposition. 

III. DEPOSITIONS

10. Number of Depositions. Plaintiff, in each of these two trial cases only, 

shall be entitled to take up to eight (8) depositions of the trial case sales representatives. 

Depositions of sales representatives previously conducted in the Discovery Pool phase shall count 

against the limit of eight (8) depositions. Of those eight depositions, plaintiff in each of these two 

trial cases may depose up to two (2) sales representative regional managers and up to two (2) 

district managers. 

11. Deposition Notices. 

a. Trial Case Sales Representatives. Absent agreement of Defendant’s 

Liaison Counsel or good cause shown, the trial case sale representatives’ depositions shall be 

noticed at least twenty (20) days in advance. 

Case 3:05-md-01699-CRB Document 2035 Filed 11/13/07 Page 4 of 5
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-5- 

PRETRIAL ORDER NO. 26: SALES REPRESENTATIVE 

DISCOVERY FOR INITIAL MDL TRIALS – M:05-CV-01699-CRB 

b. District and Regional Managers. Absent agreement of Defendant’s 

Liaison Counsel or good cause shown, the district and regional managers’ depositions shall be 

noticed at least thirty (30) days in advance. 

IT IS SO ORDERED. 

Dated: November 13, 2007 /s/ 

HONORABLE CHARLES R. BREYER 

UNITED STATES DISTRICT JUDGE 

Case 3:05-md-01699-CRB Document 2035 Filed 11/13/07 Page 5 of 5